Preserving the Promise of Cancer Immunotherapy

Melanoma Research Alliance (MRA) Context:

• MRA is the largest nonprofit funder of melanoma research, having invested over $100 million since its 2007 founding by Deborah and Leon Black.
• Melanoma remains the deadliest skin cancer, with 91,000 diagnoses and over 9,000 deaths projected in the U.S. this year (approximately one death per hour).
• A partnership with L'Oréal Paris has launched a "Skin Check Pledge" campaign, committing $100 to MRA research per sign-up, capped at $250,000.

Clinical Progress and Statistics:

• Since 2011, 11 new treatments for melanoma have been approved, shifting the landscape from low-activity agents to high-efficacy immunotherapies.
• Dr. Tony Rebus reports that while 1 in 20 patients lived with long-term benefits 15 years ago, currently 33% to 50% of metastatic patients live normal lives, including those with brain, lung, and liver metastases persisting for a decade.
• Despite these gains, approximately 50% of patients still do not respond to current checkpoint inhibitor therapies.
• Over 3,000 immunotherapy clinical trials are currently ongoing; 50% target PD-1 or PD-L1, and over 60% of trials involving 1,500 such agents are single-site, academic investigator-initiated trials.

Investment and Market Dynamics:

• Pablo Liguretta (Royalty Pharma) characterizes the current era as a "golden age of biotech," noting 5 approved checkpoint antibodies, 45 in human clinical trials, and 116 in preclinical testing.
• A significant portion of current development risks creating "Me Too" drugs; for instance, there are 45 competing PD-1 drugs in development despite the existence of approved variants like Yervoy and Opdivo.
• Investors are urged to avoid funding redundant compounds and instead prioritize smart trial design and combination therapies to ensure financial returns and patient utility.

Scientific Mechanisms and Future Directions:

• Checkpoint inhibitors (e.g., anti-CTLA-4, anti-PD-1) function by removing the "brakes" on the immune system rather than directly activating it, addressing the immune evasion tactics co-opted by cancer cells.
• Jill O'Donnell-Tormey (CRI) emphasizes the need for "reverse translation," where researchers analyze samples from responders and non-responders to understand biological deficits in the immune cycle.
• The field is moving beyond single-pathway therapies toward complex combinations of immunotherapy with chemotherapy, radiation, and other targeted agents.
• The Biden Cancer Initiative has established the Blood Profiling Atlas Consortium to develop liquid biopsies for early cancer prediction, aiming to move intervention before Stage IV diagnosis.

Collaboration and Data Infrastructure:

• Greg Simon (Biden Cancer Initiative) critiques the current research system for failing to leverage shared data, noting that no single institution possesses enough data to parse responder vs. non-responder differences effectively.
• The initiative has created a drug formulary to expedite combination trials between different industry partners and facilitated data sharing between the VA and the Department of Energy via a dedicated $4 million data network.
• There is a critical need to de-risk academic discoveries through platform trials and "incubator" models where nonprofits de-risk trials for industry partners before they enter large-scale development.

Patient-Centric Approaches:

• The panel advocates for designing clinical trials with patients from the outset to address practical barriers, such as the need for 80% of the patient population (treated in community settings) to have accessible trial options.
• The Biden Cancer Initiative is developing a patient roadmap and crowdsourcing interfaces to help patients navigate treatment choices, financial aid, and communication with family.
• Efforts are underway to mitigate immune-related side effects (e.g., type 1 diabetes, autoimmune issues) through new research funded by MRA and the American Cancer Society.

Identified Challenges and Barriers:

• Data Fragmentation: Medical records are non-standardized ("a tower of Babel"), making large-scale analysis difficult, while genomic sequencing remains cost-prohibitive for universal adoption by insurers.
• Adoption Lag: Even with breakthroughs at top institutions, it may take a decade for new therapies to reach community oncologists in rural areas due to resistance to changing established prescribing habits.
• Resource Allocation: There is a risk that the industry's focus on immunology is causing a withdrawal of investment from other critical therapeutic classes like Alzheimer's disease.

Strategic Recommendations for Continued Innovation:

• Collaboration: The consensus among panelists is that the most critical next step is increased collaboration across industry, academia, and nonprofits to avoid redundancy and share data.
• Patient as Center: Greg Simon argues that "putting patients at the center" should be the central organizing principle, driving data sharing, standardization, and trial accessibility.
• Funding Basic Science: Jill O'Donnell-Tormey stresses that sustained funding for basic science is essential to maintain the innovation pipeline for future discoveries.
• Efficiency: The panel proposes shifting from sequential single-agent trials to efficient platform trials that test combinations simultaneously without redundant control arms for patients with unmet needs.